Steatorrhea

Definition

Pathophysiology

• Robbins & Kumar Basic Pathology

Why fat is affected most severely

1. Fat digestion depends primarily on pancreatic lipase and colipase - gastric lipase can only hydrolyze up to 20% of dietary fat.
2. Lipase output falls earlier and more substantially than other enzymes (e.g., trypsin, amylase) as chronic pancreatitis progresses.
3. Lipase is more sensitive to acid inactivation than other pancreatic enzymes. As bicarbonate secretion falls, duodenal pH drops and lipase is inactivated.
4. Low duodenal pH also precipitates bile salts, preventing micelle formation and further impairing lipid digestion and absorption.
5. Lipase is more susceptible to degradation by pancreatic proteases than other digestive enzymes.

• Sleisenger and Fordtran's GI and Liver Disease

Threshold for Steatorrhea

Major Causes

1. Maldigestion (Impaired Intraluminal Processing)

• Chronic pancreatitis (alcoholic is most common - ~70% of adult cases; median time to steatorrhea: 13.1 years in alcoholic CP, 16.9 years in late-onset idiopathic CP, 26.3 years in early-onset idiopathic CP)
• Cystic fibrosis (steatorrhea in 55-88%)
• Pancreatic duct obstruction (stones, tumor)
• Necrotizing acute pancreatitis, pancreatic surgery/resection

• Advanced primary biliary cholangitis (PBC) - most important cause is decreased bile acid delivery with insufficient micellar concentration
• Ileal resection or disease (terminal ileum is the site of bile acid reabsorption; interruption of the enterohepatic circulation may prevent adequate compensation)
• When bile is completely excluded from the intestine, up to 50% of ingested fat may appear in feces, along with severe fat-soluble vitamin malabsorption
• Enterocolic fistula

2. Malabsorption (Impaired Mucosal Transport)

• Celiac disease - the most common mucosal cause of malabsorption in Western countries
• Crohn's disease - mucosal damage and/or ileal involvement
• Whipple disease - lymphatic obstruction
• Abetalipoproteinemia - defective chylomicron assembly; patients also develop neurological manifestations and acanthocytosis
• Protein-losing enteropathy - lymphatic obstruction alters lymphatic flow for lipid-containing chylomicrons, causing steatorrhea

Clinical Features

Maldigestion vs. Malabsorption - Distinguishing Features

• Sleisenger and Fordtran's, Yamada's Gastroenterology

Diagnostic Evaluation

Quantitative Fecal Fat (Gold Standard)

• Patient ingests a diet containing 100 g fat/day for 3 days, then stool is collected for 72 hours
• Normal: ≤ 7 g/day; steatorrhea: > 7 g/day (or > 14 g/day in the presence of significant watery diarrhea)
• A fecal fat concentration >9.5 g/100 g points to pancreatic/biliary maldigestion

Qualitative Stool Fat - Screening

• Sudan III staining of stool - indicates presence of steatorrhea but must be confirmed quantitatively
• Neutral fat droplets seen with EPI; free fatty acids with mucosal disease

Serum Carotenoid - Screening

• Carotenoids (major vitamin A precursors) require fat for intestinal absorption; low serum carotenoid is a simple screening test for steatorrhea
• Also low with: poor dietary intake, liver disease, high fever
• Also elevated in: hypothyroidism, diabetes, hyperlipidemia, excess dietary carotene

Pancreatic Function Tests

• Fecal elastase < 100 µg/g indicates EPI (better than fecal chymotrypsin, but not perfect sensitivity/specificity)
• Secretin stimulation test - most accurate but rarely performed (requires duodenal intubation)
• Serum trypsinogen: abnormally low levels in advanced chronic pancreatitis with steatorrhea (not decreased in other forms of steatorrhea - this distinguishes EPI from other causes)
• A therapeutic trial of pancreatic enzyme supplementation with objective monitoring (fecal fat or weight gain) is a practical diagnostic approach

Other Tests

• Anti-tissue transglutaminase (tTG) and endomysial antibodies - for celiac disease
• D-xylose absorption test - distinguishes pancreatic maldigestion (normal result) from enteropathy (abnormal)
• Schilling test for B12 - abnormal in enteric steatorrhea, not corrected by intrinsic factor
• Small bowel endoscopy with biopsy + quantitative luminal culture (for SIBO)
• CT/MRI/ERCP/EUS - for structural pancreatic/biliary assessment

Treatment

Pancreatic Enzyme Replacement Therapy (PERT) - for EPI

• Goal: deliver ≥ 90,000 USP units of lipase with each meal in the prandial and postprandial phase
• Starting dose: 40,000-50,000 units of lipase per meal (Harrison's recommends 25,000-50,000 units, with possible increase to 100,000 units)
• Enzymes should be taken with each meal and snack
• Complete correction of steatorrhea to normal levels is uncommon even with PERT
• Monitor: stool consistency, visible fat in stool, body weight, fat-soluble vitamins (especially D), zinc, bone mineral density

1. Inadequate dose (most common) - often patient non-compliance due to pill burden or cost
2. Acid inactivation of lipase - co-administer proton pump inhibitor or H2 blocker (especially with non-enteric-coated preparations)
3. Enteric-coated preparations releasing enzymes too distally (mid/distal small bowel) - adding acid suppression can help
4. SIBO as a co-existing cause

Bile Acid Deficiency

• Substitute medium-chain triglycerides (MCTs) for long-chain triglycerides (MCTs are absorbed directly into portal blood without needing micelles)
• Reduce total fat intake

Celiac Disease

• Strict gluten-free diet

SIBO

• Intermittent broad-spectrum oral antibiotics

Nutritional Support

• Fat-soluble vitamin supplementation (A, D, E, K)
• Periodic bone mineral density assessment
• Avoid very low-fat diets (worsen fat-soluble vitamin deficiencies); a Mediterranean or heart-healthy diet is reasonable
• Sleisenger and Fordtran's GI and Liver Disease, Harrison's Principles of Internal Medicine 22E (2025), Ganong's Review of Medical Physiology 26th ed.